Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety(first objective) and efficacy(second
objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age
related Macular Degeneration (AMD). The drug product is activated in patients by exposure to
light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The
exploratory objective is to assess whether it is possible to delay or reduce the requirement
for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12
weeks after VTP.
All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events
(AEs) collection).